 Connection
Wells Messersmith to Liver Neoplasms
This is a "connection" page, showing publications Wells Messersmith has written about Liver Neoplasms.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.127 |
|
|
|
-
Ueberroth BE, Kriss M, Burton JR, Messersmith WA. Liver transplantation for colorectal cancer with liver metastases. Oncologist. 2025 Jan 17; 30(1).
Score: 0.654
-
Lentz RW, Messersmith WA. Transarterial Radioembolization in Patients With Unresectable Colorectal Cancer Liver Metastases. J Clin Oncol. 2021 12 10; 39(35):3887-3889.
Score: 0.519
-
Messersmith WA, Jimeno A, Jacene H, Zhao M, Kulesza P, Laheru DA, Kahn Y, Spira A, Dancey J, Iacobuzio-Donahue C, Donehower RC, Carducci M, Rudek MA, Hidalgo M. Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. Clin Colorectal Cancer. 2010 Dec; 9(5):297-304.
Score: 0.245
-
Dasari A, McCarter M, McManus MC, Russ P, Messersmith WA. Recurrent pancreatic adenocarcinoma after pancreatic resection. Oncology (Williston Park). 2010 Dec; 24(14):1329-34.
Score: 0.245
-
Chapman BC, Paniccia A, Hosokawa PW, Henderson WG, Overbey DM, Messersmith W, McCarter MD, Gleisner A, Edil BH, Schulick RD, Gajdos C. Impact of Facility Type and Surgical Volume on 10-Year Survival in Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma. J Am Coll Surg. 2017 Mar; 224(3):362-372.
Score: 0.093
-
Benson AB, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, Messersmith W, Mulcahy MF, Murphy JD, Nurkin S, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Freedman-Cass DA. Colon cancer, version 3.2014. J Natl Compr Canc Netw. 2014 Jul; 12(7):1028-59.
Score: 0.079
-
Ray CE, Edwards A, Smith MT, Leong S, Kondo K, Gipson M, Rochon PJ, Gupta R, Messersmith W, Purcell T, Durham J. Metaanalysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma. J Vasc Interv Radiol. 2013 Aug; 24(8):1218-26.
Score: 0.073
-
Buijs M, Reyes DK, Pawlik TM, Blackford AL, Salem R, Messersmith WA, Weekes CD, Mulcahy M, Kamel IR, Geschwind JF. Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer. 2013 Mar 01; 119(5):1042-9.
Score: 0.070
-
Herman J, Messersmith W, Suh WW, Blackstock W, Cosman BC, Mohiuddin M, Poggi MM, Regine WF, Saltz L, Small W, Zook J, Konski AA. ACR Appropriateness Criteria: rectal cancer-metastatic disease at presentation. Curr Probl Cancer. 2010 May-Jun; 34(3):201-10.
Score: 0.059
-
Bartlett DL, Berlin J, Lauwers GY, Messersmith WA, Petrelli NJ, Venook AP. Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006 Oct; 13(10):1284-92.
Score: 0.046
-
Kamel IR, Bluemke DA, Eng J, Liapi E, Messersmith W, Reyes DK, Geschwind JF. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J Vasc Interv Radiol. 2006 Mar; 17(3):505-12.
Score: 0.044
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|